Stryker Co. (NYSE:SYK) Position Lowered by Reynders McVeigh Capital Management LLC

Reynders McVeigh Capital Management LLC lowered its position in shares of Stryker Co. (NYSE:SYK) by 0.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 109,621 shares of the medical technology company’s stock after selling 299 shares during the quarter. Stryker comprises 2.1% of Reynders McVeigh Capital Management LLC’s portfolio, making the stock its 15th largest position. Reynders McVeigh Capital Management LLC’s holdings in Stryker were worth $39,469,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Norges Bank bought a new position in Stryker during the fourth quarter worth $1,710,744,000. Raymond James Financial Inc. acquired a new stake in shares of Stryker during the fourth quarter worth $353,394,000. FMR LLC lifted its position in shares of Stryker by 10.0% in the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company’s stock worth $2,892,946,000 after buying an additional 727,850 shares during the last quarter. Proficio Capital Partners LLC boosted its holdings in shares of Stryker by 52,520.8% in the 4th quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company’s stock valued at $214,660,000 after buying an additional 595,061 shares during the period. Finally, APG Asset Management N.V. grew its position in shares of Stryker by 1,695.0% during the 4th quarter. APG Asset Management N.V. now owns 370,226 shares of the medical technology company’s stock valued at $128,730,000 after buying an additional 349,601 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 0.5 %

Shares of Stryker stock opened at $350.02 on Friday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The firm has a market capitalization of $133.60 billion, a PE ratio of 45.11, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The stock’s fifty day moving average is $375.54 and its 200-day moving average is $373.55.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the business posted $3.46 EPS. Equities analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.96%. Stryker’s dividend payout ratio is presently 43.30%.

Insiders Place Their Bets

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on SYK shares. Citigroup restated a “buy” rating and issued a $450.00 target price on shares of Stryker in a research note on Wednesday, February 26th. The Goldman Sachs Group set a $422.00 price objective on Stryker in a research report on Tuesday, March 4th. Barclays increased their target price on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Thursday, March 6th. Finally, Canaccord Genuity Group increased their price objective on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $423.05.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.